Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01369095 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Phase 2 study of Depression, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 976
- Enrollment target
- 20
- Study locations
NCT01369095: Completed Phase 2 study of Depression, sponsored by Bristol-Myers Squibb.
NCT01369095 is a Phase 2 study of Depression that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 976 participants, above the 785-participant average among 679 other Depression trials with a reported enrollment target (24% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01369095, a Phase 2 study of Depression, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 976 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued Duloxetine/Escitalopram in the treatment of patients with treatment resistant depression (TRD).
Conditions Studied
Interventions
- DRUG Duloxetine
- DRUG Escitalopram
- DRUG BMS-820836 Placebo
- DRUG BMS-820836
Study Locations (20)
California
- Catalina Research Institute, Llc - Chino
- Behavioral Research Specialists, Llc - Glendale
- Pacific Clinical Research Medical Group - Orange
- Anderson Clinical Research - Redlands
- Affiliated Research Institute - San Diego
- Artemis Institute For Clinical Research - San Diego
- Sharp Mesa Vista Hospital - San Diego
Florida
- Meridien Research - Brooksville
- Gulfcoast Clinical Research Center - Fort Myers
- Amit Vijapura - Jacksonville
- Stedman Clinical Trials - Tampa
- Janus Center For Psychiatric Research - West Palm Beach
Alabama
- Birmingham Psychiatry Pharmaceutical Studies, Inc. - Birmingham
Arkansas
- Arkansas Psychiatric Clinic Clinical Research Trials, P.A. - Little Rock
Colorado
- Western Affiliated Research Institute - Denver
Connecticut
- Connecticut Clinical Research - Cromwell
Georgia
- Emory University - Atlanta
Illinois
- Uptown Research Institute, Llc - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 976 participants |
| Start Date | 2011-07 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
What the finished NCT01369095 record still lists
NCT01369095 is an interventional study that assigns participants to a tested intervention. The registered 976 participants enrollment target is mid-sized for trials with a published cap, above the 785-participant average among 679 other Depression trials with a reported enrollment target (24% higher).
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 4 interventions - of which Duloxetine is the first listed.
NCT01369095 names 20 study sites across 10 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT01369095 about?
NCT01369095 is a clinical study titled "Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression". The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued Duloxetine/Escitalopram in the treatment of patients with treatment resistant depression (TRD).
What is the current status of trial NCT01369095?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 976 participants. The study started on 2011-07. Estimated completion is 2013-05.
What conditions does trial NCT01369095 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT01369095?
The interventions under investigation include: Duloxetine (DRUG), Escitalopram (DRUG), BMS-820836 Placebo (DRUG), BMS-820836 (DRUG).
Who is sponsoring clinical trial NCT01369095?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01369095 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01369095's enrollment target sits among peer trials
976 42nd of 679 higher than 638 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Neurobiology of Suicide
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05600777 · 975 participants · Phase 3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- NCT06541704 · 975 participants · Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
- NCT06820736 · 975 participants · NA
A Prospective, Randomized Comparison Of Drainage Techniques After One- Or Two-Level Open Posterior Lumbar Decompression Or Decompression And Fusion
- NCT07216482 · 975 participants · Phase 3
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia